Role of endothelin in the effects of isoprenaline on potassium currents and calsequestrin 2 expression in the heart

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 5-6, 2010, Pages 557-563

  Li, Na ^a   Jia, Nan ^a   Dai, De Zai ^a   Hu, Chen ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Arrhythmia; CASQ2; Endothelin receptor antago nist; Propranolol

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALSEQUESTRIN; CALSEQUESTRIN 2; CPU 0213; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FK 506 BINDING PROTEIN; ISOPRENALINE; PROPRANOLOL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; CAISEQUESTRIN 2, RAT; CALCIUM BINDING PROTEIN; CPU0213; POTASSIUM CHANNEL; PYRAZOLE DERIVATIVE;

ADRENERGIC ACTIVITY; ANIMAL CELL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; BETA ADRENERGIC STIMULATION; CARDIOVASCULAR EFFECT; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE; MALE; NEWBORN; NONHUMAN; POTASSIUM CURRENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STRESS; UPREGULATION; ANIMAL; ARRHYTHMIAS, CARDIAC; BIOSYNTHESIS; CELL CULTURE; COMPLICATION; DRUG EFFECTS; GUINEA PIG; MEMBRANE POTENTIAL; MENTAL STRESS; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ARRHYTHMIAS, CARDIAC; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELINS; GUINEA PIGS; ISOPROTERENOL; MALE; MEMBRANE POTENTIALS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PYRAZOLES; RATS; RECEPTORS, ADRENERGIC, BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRESS, PSYCHOLOGICAL;

EID: 77951128684     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05349.x     Document Type: Article

References (48)

1. Brugada J, Brugada R, Brugada P. Channelopathies: A new category of diseases causing sudden death. Herz. 2007 32 : 185 191.
2. Cerrone M, Noujaim S, Jalife J. The short QT syndrome as a paradigm to understand the role of potassium channels in ventricular fibrillation. J. Intern. Med. 2006 259 : 24 38.
3. Yu F, Dai DZ, Guo XF. Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Act. Pharmacol. Sin. 1997 18 : 71 4.
4. Dai DZ, Dai Y. Induced ion currents and the endothelin pathway as targets for anti-arrhythmic agents. Curr. Opin. Investig. Drugs 2008 9 : 1001 1008.
5. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ. Res. 2004 95 : 754 763.
6. Nass RD, Aiba T, Tomaselli GF, Akar FG. Mechanisms of disease: Ion channel remodeling in the failing ventricle. Nat. Clin. Pract. Cardiovasc. Med. 2008 5 : 196 207.
7. Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J. Cardiovasc. Electrophysiol. 2003 14 : S87 95.
8. Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007 93 : 483 487.
9. Jao YT, Chen Y, Lee WH, Tai FT. Thyroid storm and ventricular tachycardia. South. Med. J. 2004 97 : 604 607.
10. Zhang GQ, Ma YP, Hao XM, Zhou PA, Wu CH, Dai DZ. Rapidly activating delayed rectifier K+ current and inward rectifier K+ current in cardiomyocytes from hypertrophied guinea pig hearts induced by thyroxine. J. China Pharmaceut. Univ. 2000 31 : 451 445.
11. Zhang GQ, Hao XM, Ma YP, Zhou PA, Wu CH, Dai DZ. Characteristics of the delayed rectifier K+ currents in guinea pig hypertrophied ventricular myocytes induced by thyroxin. Chinese Pharmacol. Bull. 2001 17 : 174 177 (in Chinese).
12. Na T, Huang ZJ, Dai DZ, Zhang Y, Dai Y. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. Acta. Pharmacol. Sin. 2007 28 : 773 782.
13. Lehnart SE, Mongillo M, Bellinger A et al. Leaky Ca release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J. Clin. Invest. 2008 118 : 2230 2245.
14. Lehnart SE, Wehrens XH, Laitinen PJ et al. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 2004 109 : 3208 3214.
15. Wehrens XH, Lehnart SE, Huang F et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003 113 : 829 840.
16. Faber GM, Rudy Y. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: A simulation study of cellular mechanism. Cardiovasc. Res. 2007 75 : 79 88.
17. Wang HL, Dai DZ, Gao E, Zhang YP, Lu F. Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats. Acta. Pharmacol. Sin. 2004 25 : 738 743.
18. Wehrens XH, Lehnart SE, Huang F et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003 113 : 829 840.
19. Feng Y, Dai DZ, Na T et al. Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy. Pharmacol. Rep. 2007 59 : 306 314.
20. Li N, Jia N, Dai DZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: A role of hyperphosphorylation of PKC. Eur. J. Pharmacol. 2008 591 : 211 218.
21. Zhang Y, Huang ZJ, Dai DZ et al. Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin. Int. J. Cardiol. 2008 130 : 463 471.
22. Horkay F, Geller L, Kiss O et al. Bosentan the mixed endothelin-A- and -B-receptor antagonist suppresses intrapericardial endothelin-1-induced ventricular arrhythmias. J. Cardiovasc. Pharmacol. 2000 36 : S320 2.
23. Xia HJ, Dai DZ, Dai Y. Up-regulated inflammatory factors endothelin, NFκB, TNFα and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci. 2006 79 : 1812 1819.
24. Chen LS, Zhou S, Fishbein MC, Chen PS. New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J. Cardiovasc. Electrophysiol. 2007 18 : 123 127.
25. Cheng YS, Dai DZ, Dai Y. Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin. J. Pharm. Pharmacol. 2009 61 : 569 576.
26. Dai DZ, Huang M, Ji M, Liu LG. Endothelin receptor antagonist activity and selective blocking the ETA and ETB of compound 0213. J. China Pharm. University 2004 35 : 552 557.
27. Ellison GM, Torella D, Karakikes I et al. Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J. Biol. Chem. 2007 282 : 11397 11409.
28. Huang ZJ, Dai DZ, Li N, Na T, Ji M, Dai Y. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. Clin. Exp. Pharmacol. Physiol. 2007 34 : 310 317.
29. Li N, Yang L, Dai DZ, Wang QJ, Dai Y. Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less alpha-adrenoceptor antagonism. Clin. Exp. Pharmacol. Physiol. 2008 35 : 643 650.
30. KS in guinea-pig ventricular myocytes. Eur. J. Pharmacol. 2002 445 : 171 178.
31. Dai DZ. CPU86017: A novel Class III antiarrhythmic agent with multiple actions at ion channels. Cardiovasc. Drug Rev. 2006 24 : 101 115.
32. Dai DZ, Wang HL, Zhang GQ, He GX, Chen L. Matrix is the site of indirect effects of propranolol on the ion channelopathies in cardiac remodeling by L-thyroxine. J. Card. Surg. 2002 17 : 439 446.
33. Yontar OC, Yalta K, Yilmaz MB, Turgut OO. Short QT syndrome: A very rare arrhythmogenic entity. Acta Cardiol. 2008 63 : 553 555.
34. Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm. 2008 25 : 585 590.
35. Piepoli MF, Capucci A. Autonomic nervous system in the genesis of arrhythmias in chronic heart failure: Implication for risk stratification. Minerva Cardioangiol. 2007 55 : 325 333.
36. Osadchii OE, Norton GR, McKechnie R, Deftereos D, Woodiwiss AJ. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation. Am. J. Physiol. Heart Circ. Physiol. 2007 292 : H1898 905.
37. Yamamoto S, Matsumoto N, Kanazawa M, Fujita M, Takaoka M, Matsumura Y. Effects of ET (A) and ET (B) receptor blockade on post-ischemic cardiac dysfunction and norepinephrine overflow in isolated rat hearts. J. Cardiovasc. Pharmacol. 2004 44 (Suppl 1 S394 7.
38. Volders PG, Stengl M, van Opstal JM et al. Probing the contribution of IKs to canine ventricular repolarization: Key role for beta-adrenergic receptor stimulation. Circulation 2003 107 : 2753 2760.
39. Stengl M, Ramakers C, Donker DW et al. Temporal patterns of electrical remodeling in canine ventricular hypertrophy: Focus on IKs downregulation and blunted beta-adrenergic activation. Cardiovasc. Res. 2006 72 : 90 100.
40. Abi-Gerges N, Small BG, Lawrence CL, Hammond TG, Valentin JP, Pollard CE. Gender differences in the slow delayed (IKs) but not in inward (IK1) rectifier K+ currents of canine Purkinje fibre cardiac action potential: Key roles for IKs, beta-adrenoceptor stimulation, pacing rate and gender. Br. J. Pharmacol. 2006 147 : 653 660.
41. Jost N, Virág L, Bitay M et al. Restricting excessive cardiac action potential and QT prolongation for IKs in human ventricular muscle: A vital role for IKs in human ventricular muscle. Circulation 2005 112 : 1392 1399.
42. Williams BA, Dickenson DR, Beatch GN. Kinetics of rate-dependent shortening of action potential duration in guinea-pig ventricle; effects of IK1 and IKr blockade. Br. J. Pharmacol. 1999 126 : 1426 1436.
43. Shah RR. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacol. Ther. 2008 119 : 215 221.
44. Pratt CM. Pure class III agents for prevention of sudden cardiac death. J. Cardiovasc. Electrophysiol. 2003 14 : S82 6.
45. Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. J. Cardiovasc. Electrophysiol. 2007 18 : 791 797. (Pubitemid 46934514)
46. Chopra N, Kannankeril PJ, Yang T et al. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice. Circ. Res. 2007 101 : 617 626.
47. Xu J, Li N, Dai DZ, Yu F, Dai Y. The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase, ETA, ETB, and MMP9 in the vasculature. J. Cardiovasc. Pharmacol. 2008 52 : 42 8.
48. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J. Cardiovasc. Pharmacol. 2006 47 : 729 735.